Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
INBX on Nasdaq
Shares outstanding
14,560,641
Price per share
$73.49
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
12,777,713
Total reported value
$1,009,430,929
% of total 13F portfolios
0%
Share change
+2,190,762
Value change
+$184,315,391
Number of holders
136
Price from insider filings
$73.49
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VIKING GLOBAL INVESTORS LP 10% $106,593,674 1,454,608 VIKING GLOBAL INVESTORS LP 31 Dec 2025
MORGAN STANLEY 7.9% $84,668,884 1,155,416 Morgan Stanley 31 Dec 2025
Kayyem Jon Faiz 7.9% $13,765,571 1,149,046 Jon Faiz Kayyem 03 Jun 2024
Lappe Mark 6.4% $11,086,448 925,413 Mark Lappe 12 Sep 2024
BlackRock, Inc. 5.3% +12% $60,682,270 +$6,933,198 768,130 +13% BlackRock, Inc. 31 Dec 2025

As of 31 Dec 2025, 136 institutional investors reported holding 12,777,713 shares of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX). This represents 88% of the company’s total 14,560,641 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
PERCEPTIVE ADVISORS LLC 10% 1,452,707 +9.4% 2.1% $114,763,853
VIKING GLOBAL INVESTORS LP 9.9% 1,437,705 -20% 0.3% $113,578,695
MORGAN STANLEY 8% 1,167,728 +164% 0.01% $92,250,538
Sanofi 8% 1,157,926 0% 29% $91,476,154
HighTower Advisors, LLC 6% 870,507 -0.14% 0.08% $68,770,053
BlackRock, Inc. 5.3% 777,383 +14% 0% $61,413,257
VANGUARD GROUP INC 4.3% 623,084 +4.7% 0% $49,223,636
Sofinnova Investments, Inc. 3.1% 454,657 +3.3% 1.5% $35,917,903
Capital Research Global Investors 2.9% 421,575 0.01% $33,304,425
STATE STREET CORP 2.6% 374,961 +84% 0% $29,621,919
Caligan Partners LP 2.2% 323,565 +37% 2.3% $25,561,635
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2% 297,116 0.03% $23,472,164
MILLENNIUM MANAGEMENT LLC 1.9% 275,917 -7.4% 0.02% $21,797,443
PFM Health Sciences, LP 1.8% 265,517 +11% 2.1% $20,975,843
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 1.8% 264,000 0.04% $20,856,000
GEODE CAPITAL MANAGEMENT, LLC 1.6% 226,009 +1.8% 0% $17,858,743
Schonfeld Strategic Advisors LLC 1.5% 214,725 +120% 0.09% $16,963,275
Woodline Partners LP 0.96% 139,479 -59% 0.04% $11,018,841
NORGES BANK 0.92% 133,300 0% $10,530,700
D. E. Shaw & Co., Inc. 0.84% 122,101 +957% 0.01% $9,645,979
Invesco Ltd. 0.77% 112,396 +540% 0% $8,879,284
CDC Financial, Inc. 0.76% 110,810 0% 8.1% $8,753,990
GOLDMAN SACHS GROUP INC 0.69% 100,617 +287% 0% $7,948,743
BOOTHBAY FUND MANAGEMENT, LLC 0.63% 92,009 +17% 0.19% $7,268,711
NORTHERN TRUST CORP 0.61% 88,509 -4.5% 0% $6,992,211

Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 12,777,713 $1,009,430,929 +$184,315,391 $79.00 136
2025 Q3 10,497,334 $353,550,847 +$6,764,063 $33.68 101
2025 Q2 10,435,616 $148,917,132 -$5,468,523 $14.27 87
2025 Q1 10,790,279 $150,950,613 -$5,227,676 $13.99 92
2024 Q4 11,165,626 $171,927,470 +$10,221,839 $15.40 101
2024 Q3 8,897,409 $139,328,871 -$10,813,194 $15.66 95
2024 Q2 9,650,613 $136,747,433 +$136,582,849 $14.17 86